Suzanne Saffie-Siebert
Founder & Chief Executive Officer SiSaf Ltd
Chairwoman and CEO of SiSaf Ltd, Suzanne Saffie-Siebert leads the development of innovative RNA delivery technologies. With nearly two decades at the company, she has pioneered silicon-stabilised hybrid LNP platforms to enhance stability, safety, and effectiveness of RNA therapeutics.
Seminars
Wednesday 23rd September 2026
Introductory Panel: Identify Which LNP Applications Will Deliver Clinical & Commercial Success Across Emerging Modalities
9:00 am
A cross-disciplinary panel bringing together leaders working across the most advanced and emerging applications of LNP delivery, including srRNA, gene editing, in vivo cell therapy, oncology, autoimmune disease and protein replacement.
- Compare delivery requirements across different therapeutic modalities
- Identify where LNPs are already working vs where they are still failing
- Understand how application choice impacts design, toxicity and manufacturability
- Evaluate which areas are overhyped vs commercially viable
- Explore how hybrid systems (lipids, polymers, peptides) are expanding capability
